Using PET Imaging to Optimize Drug Dosing in Bladder Cancer
Author Information
Author(s): Mishra Akhilesh, Sharma Ajay Kumar, Gupta Kuldeep, Banka Dhanush R., Johnson Burles A., Hoffman-Censits Jeannie, Huang Peng, McConkey David J., Nimmagadda Sridhar
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
Can Nectin-4-targeted PET imaging improve dosing strategies for enfortumab vedotin in urothelial carcinoma?
Conclusion
Nectin-4-targeted PET imaging is a reliable predictor of therapeutic efficacy and can help optimize dosing strategies for enfortumab vedotin in bladder cancer.
Supporting Evidence
- PET imaging revealed dose-dependent variations in Nectin-4 engagement.
- Suboptimal EV doses resulted in incomplete Nectin-4 engagement and reduced tumor growth.
- Target engagement measured by PET was a more reliable predictor of therapeutic efficacy than dose or baseline Nectin-4 expression.
Takeaway
This study shows that a special imaging technique can help doctors give the right amount of medicine to treat bladder cancer better.
Methodology
The study used Nectin-4-targeted PET imaging to assess target engagement in preclinical models of urothelial carcinoma.
Limitations
The study may be limited by the preclinical nature of the models used and the specific focus on Nectin-4.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website